Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative EMDA mitomycin C versus postoperative passive-diffusion mitomycin C in non-muscle-invasive bladder cancer
2022-004112-28Phase 4Active
- Sponsor
- Guillem Abad CarratalÃ
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC) (2 arms), sponsored by Guillem Abad CarratalÃ. Primary endpoints: Recurrence and progression rates and Time free until first event. Started Jan 2023; status: active.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2022-004112-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004112-28.